Form 8-K - Current report:
SEC Accession No. 0001595585-23-000004
Filing Date
2023-01-04
Accepted
2023-01-04 16:22:24
Documents
13
Period of Report
2022-12-28
Items
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcda-20221228.htm   iXBRL 8-K 36563
5 GRAPHIC tcda-20221228_g1.jpg GRAPHIC 34563
  Complete submission text file 0001595585-23-000004.txt   261655

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tcda-20221228.xsd EX-101.SCH 1912
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tcda-20221228_lab.xml EX-101.LAB 25149
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tcda-20221228_pre.xml EX-101.PRE 13056
7 EXTRACTED XBRL INSTANCE DOCUMENT tcda-20221228_htm.xml XML 11324
Mailing Address 7000 SHORELINE COURT, SUITE 201 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT, SUITE 201 SOUTH SAN FRANCISCO CA 94080 415-429-7800
Tricida, Inc. (Filer) CIK: 0001595585 (see all company filings)

EIN.: 463372526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38558 | Film No.: 23506766
SIC: 2834 Pharmaceutical Preparations